1. In Vivo
  2. >>Manufacturing Focus

A Convergence Problem: Getting the Drug on the Device

Drug-eluting stents are highly successful medical devices but even their manufacturers don't have adequate solutions for a hidden problem in drug-device combinations; the best way to get the drug on the device. Sarnoff Corp.has a new technology for addressing this complex process. Called electro-static deposition, it brings increased flexibility, reproducibility, accuracy, and uniformity to a manufacturing process which using current methods is costly and inefficient,

Drug-eluting stents are one of the most successful medical devices ever, but even their manufacturers don't have adequate solutions for a hidden problem in drug-device combination products: the best way to get drugs on devices on a large scale. That's the contention of Russ Granzow, who is head of the life sciences and health care operations at SRI International division Sarnoff Corp. , a technology development company.

Although tens of thousands of drug-coated stents run through manufacturing plants each day, making them is a relatively manual process....

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Manufacturing Focus

Rising Leaders 2025: How Christina Smolke Turned Research Into Real World Impact

 
• By David Wild

The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.

Future Proofing Gene Therapy Assays For Regulatory Success

 
• By Deborah Phippard

As gene therapy advances and regulations tighten, biopharma companies face growing pressure to design diagnostic assays that are both flexible and future ready. Strategic early investment in assay development can prevent costly delays and rework as therapies progress toward approval.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

More from In Vivo

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Deals In Depth: July 2025

 
• By Deanna Kamienski and Maureen Riordan

Six $1bn+ alliances were penned in July, and two exceeded $2bn.

Execs On The Move: July 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.